Poland Country Drug Report 2019

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

In Poland, drug-related public expenditure was first reported in 2012. The amounts reported include estimates for the funding of all non-governmental organisations that deal with demand reduction.

The central, regional and local governments reported drug-related expenditure, in the framework of the monitoring of the National Anti-Drug Strategy implementation. Estimates for 2014 and 2015 suggest that drug-related expenditure was at least EUR 25.8 million and EUR 35.5 million, respectively, amounting to least 0.01 % of the annual gross domestic product (GDP). However, these estimates do not include data from all units of the central government. Estimates for 2016 are expected in the near future.

Poland main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.